Participated · Series A · Apr 2023

Orbital Therapeutics is building a first-in-kind RNA platform that integrates established and emerging RNA technologies, delivery mechanisms, data science and automation to broaden the reach of RNA medicines. The company is focused on next-generation vaccines, immunomodulation, and protein replacement, and seeks to extend the durability of RNA therapeutics while expanding delivery to a wide range of cell types and tissues. Orbital excludes small interfering RNA from its stated remit and emphasizes platform-driven discovery and development. The company describes itself as founded by experts in genetic medicine and RNA development and delivery. Recent corporate growth included executive hires to support development and operations. The financing announced will support expansion of the platform and portfolio toward patient-facing programs.

Participated · Series B · Oct 2022

Neumora Therapeutics is a clinical-stage biotechnology company integrating data science and neuroscience to develop precision medicines for neuropsychiatric and neurodegenerative disorders. The company is advancing a data-driven precision neuroscience platform and patient enrichment strategies intended to cut through brain disease heterogeneity and better match patients to targeted therapeutics. Its pipeline includes seven development programs spanning clinical and preclinical stages, with a mix of clinically validated and novel approaches. Neumora recently completed enrollment in a Phase 2a trial for NMRA-140, and is progressing clinical-stage NMRA-511 and NMRA-266 toward Phase 1 initiation in 2023; earlier-stage programs target Parkinson’s disease and ALS. The company says the financing and prior capital give it a very strong financial position to advance multiple near-term, value-creating milestones. Neumora has operations in the Greater Boston Area and South San Francisco. Neumora builds a scalable precision data science platform that integrates genomics, imaging, EEG, digital and clinical data to define patient subtypes via Data Biopsy Signatures™ and Precision Phenotypes™. The company’s core product approach is to match targeted therapeutics to enriched patient populations to de-risk trials and improve probability of success. Neumora has assembled a pipeline of eight clinical, preclinical and discovery-stage programs sourced from internal discovery, acquisitions of private companies and license agreements with Amgen. The company says it was launched to transform neuroscience R&D away from broad symptom-based classifications toward mechanism-driven precision medicines. Neumora plans to advance its portfolio across neuropsychiatric and neurodegenerative diseases using its neural-network toolbox and multi-modal datasets. Financially, Neumora has raised over $500 million, including a separately announced $100 million equity investment from Amgen, and operates in the Greater Boston Area and South San Francisco.

Participated · Series E · Mar 2022

Getir operates as a large food delivery company. The article lists a $250M fundraising for Getir. It also reports the company is restructuring into two separate businesses. The piece frames the raise as one of the week's notable and big funding rounds. No revenue, user metrics, investors, or instrument details were provided in the article. Getir is described in the announcement as one of the world’s leading logistics and technology companies offering hyper-fast delivery. Its core product is a hyper-fast delivery service built on logistics and technology capabilities. The company has, according to Flat Capital, demonstrated a dominant position despite a challenging market. Prominent investors are on its shareholder list, including Sequoia Capital and Mubadala Investment Company. Flat’s continued investment signals investor confidence and an expectation of opportunities to continue growing and creating a unique position in attractive markets. Getir operates an ultrafast grocery delivery service that uses company-owned micro-fulfillment centers (dark stores) and owned inventory to assemble orders for bike and scooter couriers. Customers can place orders without selecting delivery slots and typically receive deliveries within about 20–40 minutes. The company has expanded rapidly from its origins in Turkey to operate across nine countries, including the U.K., Germany, France, Italy, Spain, Netherlands, Portugal and the U.S. Getir reports roughly 40 million app downloads and manages about 1,100 dark stores. It is dominant in Turkey (operating in 81 cities) and covers 48 cities across its other markets. Management says the company will invest further in its proposition, technology and employees to continue growing in a capital-intensive, crowded market. Getir operates a rapid grocery delivery service that offers around 1,500 everyday items delivered to customers in minutes, seven days a week, day and night. The company runs multiple sub-brands including GetirFood, GetirMore, GetirWater and GetirLocals. It is active in 30 cities across Turkey and launched operations in the UK in January 2021 and the Netherlands in May 2021. Getir intends to use the new funding to continue its expansion into the United States. Financially, the company raised significant capital in 2021, marking this as its third round of the year and contributing to nearly $1bn raised since the start of 2021. Founded in 2015 by Nazim Salur, Serkan Borancili and Tuncay Tutek, Getir leverages founders' backgrounds in local taxi apps, e‑commerce exits and consumer goods leadership. Getir is an Istanbul-based startup founded in 2015 that operates a grocery delivery app offering deliveries in as little as ten minutes. Customers order groceries via its mobile app, and the company has begun international expansion, recently launching service in London. Getir reported that its revenues grew five-fold in 2020. The company has been an active fundraiser amid a broader investor rush into grocery delivery apps during the pandemic. Market interest is driven by accelerated consumer adoption of online grocery delivery in Europe.

Participated · Series C · Feb 2022

Savage X Fenty sells body-positive lingerie and is expanding into apparel, including a planned line of athletic wear. The company is pursuing a brick-and-mortar retail strategy and international growth in Europe, with plans to open 10 physical stores in 2022 and additional locations in Los Angeles, Houston, Philadelphia and the D.C. area. Its first storefront in Las Vegas features a tech-enabled fit experience using body scans and augmented reality to provide product recommendations. The brand has experienced rapid growth, reporting 200% sales growth in 2020, and aims to be a global leader in the lingerie market by 2025. To date the company has raised $310 million in total; its latest round did not disclose a new valuation, according to CultureBanx. Savage x Fenty is Rihanna's inclusive lingerie and apparel brand that sells direct-to-consumer products and operates a subscription business. Launched in 2018 as a joint venture with TechStyle Fashion Group, the brand is known for inclusive sizing and high‑visibility fashion shows. The company said revenues increased 200% in 2020 and its subscription membership grew 150%; sources reported sales were on track to hit $150 million in 2019. Savage x Fenty has 3.9 million Instagram followers, and Forbes estimated Rihanna's stake at about $80 million prior to the new funding. The company raised $115 million in the latest Series B, bringing total capital raised to $185 million to date. Proceeds are expected to fund retail expansion and a possible line of athletic wear.

Led · Series F · Nov 2021

Cerebras Systems designs and sells what it describes as the fastest AI infrastructure in the world, centered on its Wafer-Scale Engine 3 (WSE-3) processor. The company states the WSE-3 is the largest commercialized AI processor, 58 times larger than the largest GPU, delivering inference and training up to 15 times faster while using a fraction of the power per unit compute. Cerebras offers solutions both on premises and in the cloud and reports deployments with leading corporations, research institutes, and governments across four continents. Financially, the company completed a $1 billion Series G in September 2025 and a $1 billion Series H in January 2026, and has now secured an $850 million revolving credit facility, bringing total capital raised to $2.85 billion in the last eight months. The company intends to use the new credit facility to expand data center capacity and support its growth plans.